Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease

@inproceedings{Emdin2017GeneticVA,
  title={Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease},
  author={Connor A Emdin and Derek Klarin and Pradeep Natarajan and Jose C Florez and Sekar Kathiresan and Amit V. Khera},
  booktitle={Diabetes},
  year={2017}
}
Despite widespread clinical use in the treatment of type 2 diabetes, the impact of sulfonylurea therapy on cardiovascular outcomes remains uncertain. Studies of naturally occurring genetic variation can be used to anticipate the expected clinical consequences of a pharmacological therapy. A common missense variant in the gene encoding a component of the sulfonylurea receptor (ABCC8 p.A1369S) promotes closure of the target channel of sulfonylurea therapy and is associated with increased insulin… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 55 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 26 references

A genomic approach to therapeutic target validation identi fi es a glucose - lowering GLP 1 R variant protective for coronary heart disease

  • SP Marso, GH Daniels, K Brown-Frandsen
  • Sci Transl Med
  • 2016

: a patient - centered approach : update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

  • Y Li, Y Hu, SH Ley, S Rajpathak, FB Hu
  • Diabetes Care
  • 2015

Similar Papers

Loading similar papers…